

**To:** [redacted] [redacted]@rivm.nl]  
**From:** [redacted]  
**Sent:** Mon 9/21/2020 10:53:53 AM  
**Subject:** For October 8: Preliminary results from the survey and extra data from EVAG  
**Received:** Mon 9/21/2020 10:53:55 AM  
[figures.pdf](#)  
[Manuscript\\_BB.pdf](#)  
[COVID19survey\\_updated-1.pptx](#)

Hi [redacted]

For the updates on the EVAG project, you can see attached:

- The presentation from [redacted] with the preliminary results from our survey on non-monetary benefit sharing
- The extra data sent from [redacted] [redacted] on the activities being performed by the infrastructure.

Let me know if you have any doubts.

Best,

[redacted]

---

**From:** [redacted] <[redacted]@univ-amu.fr>  
**Sent:** woensdag 16 september 2020 10:54  
**To:** [redacted] <[redacted]@dsmz.de>; [redacted] <[redacted]@dsmz.de>; [redacted] <[redacted]@rivm.nl>  
**Subject:** Data WP7 EVAG Covid19

Dear all,

Following our meeting yesterday, as an example, here is the manuscript of the paper that was submitted last week to the biobanking journal I mentioned, regarding distribution of EVAG products globally during the Covid10 pandemic. You will see the type of figures I can produce by extracting data from our database (only covering the first three months of the pandemic in this case).

As I said, I would rather wait to have a discussion with you guys on what we want to show exactly, before starting digging into data, because it will save me a lot of time. Having said that, I've put together just last week a nice Excel workflow for tracking EVAG activity, so that would be the perfect occasion for me to Beta-test it :-).

Have a good rest of the day

[redacted]

--

[redacted]  
[redacted]

**European Virus Archive GLOBAL (EVA-G)**

Office: [redacted]

Mobile: [redacted]

<https://www.european-virus-archive.com>

Unité des Virus Emergents (UVE)

Aix-Marseille Université-IRD 190-INSERM 1207-IRBA

IHU Infection, 19-21 Bd Jean Moulin, 13005 MARSEILLE, France

